I’m sure everybody at Anavex understands that the company will circle the drain if/when Blarcamesine is formally turned down (+90% likelihood) at which point the company will have to reduce cash burn by firing most of the bloated staff. If I worked at Anavex, I’d be updating my resume and reaching out to industry contacts and looking for a new job before the firing starts.
As far as Mayo goes, his brief career as a self-appointed “biotech analyst” who tells retail exactly what they want to hear will be over if/when Anavex implodes.
Market Data 
Markets 
AI
